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INTRODUCTION
The Diego blood group represents the 10th red cell antigen
system classified according to the International Society for
Blood Transfusion (ISBT), which mainly consists of two inde-
pendent pairs of antigens, called Di
a/Di
b and Wr
a/Wr
b. Each
pair contains a low-incidence antigen and an antithetical high-
incidence determinant, respectively (1, 2). As mentioned, the
Di
a antigen is well known as one of the antigens with low inci-
dence (0.01%) among Caucasians; however, it shows a rela-
tively higher incidence among native American Indians and
Asian-Mongoloid populations, which therefore demonstrates
unique anthropologic significance (1-4). South American
Indians have been shown to have an incidence of Di
a antigen as
high as 36%, Chippewa Indians an incidence of 11%, Chinese
an incidence of 5%, Japanese an incidence of 12%, and Koreans
an incidence of 6.4-14.5% (3, 4). The cases of hemolytic trans-
fusion reactions (HTRs) and hemolytic disease of the newborns
(HDNs) related to anti-Di
a have been sporadically reported
in the world, and these include severe cases (5-8). A few cases
of anti-Di
a have been found in Korean patients who received
repeated transfusions, and a case of HDN due to anti-Di
a was
reported recently (3, 9). Therefore, for safer transfusion, it is
extremely important that patients with anti-Di
a receive Di
a
antigen-negative blood. Since a limited number of Caucasians
carry the Di
a antigen, the Di
a+ cell is hardly a part of antibody
screening panels. Anti-Di
a have been found only sporadically
even in the Asian-Mongoloid countries, because most Asian
countries adopt identical panel cells used in Caucasians. In
this study, the authors incorporated the Di
a+ panel cell into
antibody screening tests to estimate the incidence of anti-Di
a
among Korean populations and also to evaluate its clinical
significance.
MATERIALS AND METHODS
The authors examined the incidence of anti-Di
a in 11,219
patients who visited Pusan National University Hospital from
March 2001 through March 2003 and received antibody
screening test. The column agglutination method using LISS/
Coombs card (DiaMed AG, Cressier, Morat, Switzerland) was
used for the antibody screening test, with ID-DiaCell I+II
(DiaMed AG) and ID-DiaCell Di
a+ (DiaMed AG) as screen-
ing panel cells. The antibody identification test was conduct-
ed for those with positive results from the antibody screening
test.
Antibody Screening Test
Fifty  L screening cells and 25  L serum were added to LISS/
Coombs card (DiaMed AG) and incubated at 37℃for 15 min.
Using ID-Centrifuge (DiaMed AG), it was further centrifuged
for 10 min. The results were interpreted as 5 phases : negative,
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The Clinical Significance of Antibody Screening Test Including
Di
a+ Panel Cell in Asian-Mongoloid Populations
The Di
a antigen is well known as one of the antigens with low incidence among
Caucasians; however, it has been discovered with a relatively higher incidence
among Mongoloid populations. Thus, it has been speculated that the incidence
of unexpected antibody against the Di
a antigen might be relatively higher among
these populations. Hemolytic transfusion reactions (HTRs) and hemolytic disease
of the newborns (HDNs) caused by anti-Di
a have been reported sporadically. How-
ever, there has been no prospective study on the incidence of anti-Di
a in Mongoloid
populations particularly. The authors conducted a series of antibody screening
tests on 11,219 Korean individuals for 25 months, by using three kinds of screening
cells including Di
a cell. Anti-Di
a was detected in 8 patients, seven of whom had a
history of transfusions or were multigravida. The incidence of anti-Di
a measured in
this study was higher than expected, ranked third among unexpected antibodies
identified during the period of the study, so it is strongly recommended that the Di
a+
panel cell must be incorporated into antibody screening test for safer transfusion in
Asian-Mongoloid populations.
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1+, 2+, 3+, and 4+. If all of the red blood cells precipitated
to the bottom of the column, the result would be negative,
whereas if the red blood cells aggregated at the very top of the
column the result would be 4+. The rest was interpreted ac-
cording to the 1-4 grading system.
Antibody Identification Test
A method similar to the antibody screening test was used
with Set ID-Diapanel (DiaMed AG) and with the identical
interpretation system.
RESULTS
Of 11,219 patients who took the antibody screening test
using LISS/Coombs card (DiaMed AG), positive results were
found in 135 cases, with a 1.2% detection rate of unexpected
antibody, and the distribution was as follows: the antibodies
with highest detection rates were anti-E (36 cases), anti-Le
a
(15 cases), anti-Di
a (8 cases), anti-M (6 cases), anti-E+anti-c
(6 cases), anti-D (3 cases), and anti-e+anti-C (3 cases) with
descending order. Anti-Di
a was detected in 3 men and 5 wo-
men, and in six of them the unexpected antibodies were further
evaluated through Di
a antigenic phenotyping, enzyme phase,
and additional tests using other panel cells (Table 1). All of
the women with anti-Di
a was multi-gravida and transfusions,
and two of three men also had a history of at least two episodes
of transfusion of red cell concentrates. However, no transfu-
sion history was documented in one of the male patients. In
total, anti-Di
a was detected in 8 out of 11,219 patients, with
its detection rate of 1/1,402 (0.07%). Anti-Di
a was not accom-
panied by other alloantibodies in each of the patients.
DISCUSSION
The clinically important unexpected antibodies causing
HTRs or HDNs are usually formed as a result of exposure to
red cell antigens from other persons through repeated trans-
fusions or pregnancies (1-4). Based on recent studies of west-
ern countries, the clinically significant unexpected antibodies
that occurred with the highest incidence after transfusion were
anti-E and anti-Jk
a in common (10-13). In our country, the
results of antibody screening test showed a large variation in
terms of incidence and distribution of unexpected antibodies
related to reported time and used methods (3, 14-16). The
reports before 1990 using tube method showed the highest
incidence of cold antibodies such as anti-Le
a and anti-P1, which
are less clinically significant (3, 14). Since the late 1990s in
which column agglutination method was adopted, the high-
er incidence was found in anti-E or anti-E+anti-c depending
on researchers, which is similar to the incidence measured in
other countries (3, 15, 16). The identical pattern of the dis-
tribution was found in our study, which showed a higher inci-
dence of unexpected antibodies against Rh blood group except
anti-Di
a with a high detection rate.
The Diego blood group represents the 10th red cell antigen
system classified according to the ISBT, which consists of a
total of 21 antigens (1, 2). Among these, Di
b and Wr
b antigens
belong to the high-incidence antigen groups without ethnic
variation; however, other antigens including the Di
a antigen
belong to the low-incidence antigen groups (1-3). The Di
a
antigen is rarely found in Caucasians, and thus no active screen-
ing test is conducted for detection of anti-Di
a. The incidence
of Di
a antigen is, however, relatively higher among the Mon-
goloid Asians and native American Indians from 3-4% up to
36%, which represents a unique anthropologic significance
(1-4). Chae et al. have reported that Koreans have an 8.2%
incidence of the Di
a antigen, similar to those Mogolian Asians
(17). They also reported only one case of anti-Di
a in their series,
with its detection rate of 1/1,846 (0.05%) (17). Although many
Asian countries including Korea have been predicted to have
a relatively higher incidence of anti-Di
a, the panel cells iden-
tical to those for Caucasians are used in the antibody screening
test, and only a few sporadic cases have been reported on this
issue (5-9). In this study, anti-Di
a alone, unaccompanied by
any other alloantibodies, was identified in eight patients. Be-
cause of its limited availability of Di
a+ panel cells, it has been
difficult to entirely rule out the possibility of the unexpect-
1 F/28 O+ NT Tennis elbow G2P2A0L2 Yes
2 F/29 B+ NT Delivery, previous pelvic bone fracture G4P1A2L1 Yes
3 F/35 AB+ - Thyroid papillary cancer G2P2A0L2 Yes
4 F/37 A+ - Idiopathic thrombocytopenic purpura G3P1A2L1 Yes
5 M/44 O+ - Common bile duct stone - Yes
6 M/25 O+ - Left acetabular fracture - Yes
7 M/53 O+ - Tongue cancer - NI
8 F/44 A+ - Acute monoblastic leukemia (M5a) G5P3A2L3 Yes
No. of
patient
Sex/Age Blood group
Di
a antigen
phenotype
Diagnosis
Obstetrical
history
Transfusion
history
Table 1. Summary of clinical characteristics in eight patients with anti-Di
a
NT, not tested; NI, no information; -, negative; G, gravida; P, parity; A, abortion; L, living birth.Anti-Di
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ed antibodies present in any form of multiple alloantibodies
consisting also of anti-Di
a. However, it is important at this
point to mention that no immediate hemolytic reaction had
occurred during this research even if multiple alloantibodies,
including anti-Di
a, were present. The reason for this is that
adequate source of blood was issued upon cross-match between
patient’s serum and the given antigen negative blood by using
indirect anti-globulin method, which was done among all of
the patients with unexpected antibodies.
Type and screen is a policy in which the patient’s blood
sample is tested for ABO, RhD, and unexpected antibodies,
then stored in the blood bank for future cross-match (1). If
the result of antibody screening test is positive, the antibody
must be identified and antigen-negative units for the clini-
cally significant antibodies must be available for use if needed.
However, if the antibody screen is negative, ABO- and Rh-
compatible blood can be safely released after an immediate-
spin or electronic cross-match (1, 3). Currently, a large num-
ber of medical institutions in Korea have adopted column
agglutination method as antibody screening test instead of
using traditional tube method. Along with this trend of appli-
cation, the ‘‘type and screen’’ policy has also been implemented
by an increasing number of hospitals. But the condition or
obligation to this policy is that the panel cells used in screen-
ing must include all of the clinically significant antigens pos-
sessed by the specific group of people or race. The usual com-
mercialized screening cells are produced on the basis of RBC
antigen phenotypes of Caucasian. These blood cells generally
include Rh, Kell, Duffy, Kidd, Lewis, P, MNSs, Lutheran, and
Xg blood group antigens. Therefore, if clinically significant
RBC antigens other than the above mentioned antigens are
found within particular race, the cells having related antigens
should be added to usual screening cells, bringing the even
more safer ‘‘type and screen’’ possible. For example, the Mil-
tenberger (Mi) classes represent a group of phenotypes of red
cells that carry low frequency antigens associated with the
MNSs blood group system (18). However, the Miltenberger
class III phenotype (MiIII) has a relatively high incidence among
people in South-East Asia: 9.7% in Thais, 7.3% in Taiwanese
Chinese and 6.28% in Chinese blood donors in Hong Kong
(19-21). Lin et al. reported that anti-Mi was the most com-
mon atypical alloantibody in both inpatients and pregnant
women among Chinese patients in Hong Kong, being detect-
ed in 0.34% and 0.46% of them, which accounts for 31% and
48% of the total number of detected alloantibodies, respec-
tively (19). For this reason, they recommended that MiIII cells
should be included in screening panels when conducting type
and screen on local Chinese population (19).
In our opinion, difference in the incidence of anti-Di
abetween
reports is not caused by actual difference in the anti-Di
a inci-
dence, but because there is no addition of race-specific screen-
ing cells into antibody screening test. In conclusion, we strong-
ly suggest that the Di
a+ panel cell should be incorporated into
antibody screening tests conducted among Korean and Asian-
Mongoloid populations for safer transfusion.
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